• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
LI Lin, WANG Xiaoming, MENG Shufang, CHEN Lin, WANG Haiyan, LIN Pengfei, CHEN Ling. Preparation process and structure confirmation of impurity C of rupatifen fumarate[J]. Journal of China Pharmaceutical University, 2020, 51(5): 530-537. DOI: 10.11665/j.issn.1000-5048.20200504
Citation: LI Lin, WANG Xiaoming, MENG Shufang, CHEN Lin, WANG Haiyan, LIN Pengfei, CHEN Ling. Preparation process and structure confirmation of impurity C of rupatifen fumarate[J]. Journal of China Pharmaceutical University, 2020, 51(5): 530-537. DOI: 10.11665/j.issn.1000-5048.20200504

Preparation process and structure confirmation of impurity C of rupatifen fumarate

Funds: This study was supported by China National Key Hi-Tech Innovation Project for the R&D of Novel Drugs(No.2018ZX09J18108-005) and Fujian Provincal Science and Technology Major Special Project(No.2015YZ0002-2)
More Information
  • Received Date: November 24, 2019
  • Revised Date: August 09, 2020
  • The high-purity impurity C was isolated and purified from a new anti-allergic drug, rupatifen, by nucleophilic substitution reaction with bromobutaric acid, and its structure was confirmed by IR, UV, MS, 1H NMR, 13C NMR, DEPT135°,HSQC, HMBC, and 1H-1HCOSY. The preparation process of impurity C in this study was simple and easy to obtain under mild conditions, with the purity of 99.0% and the yield of 25%-30%;and the sample met the target compound by structural confirmation. The preparation process and structure confirmation provided sufficient impurity C reference substance for impurity research of raw materials and preparations of rupatifen fumarate, which laid a solid foundation for quality research of new drugs.
  • [1]
    .2016-06-01.
    [2]
    Fujian Mindong Rejuvenation Pharmaceutical Co.,Ltd.Rupatifen fumarate impurity C, preparation method and detection method thereof:CN,
    201811043105.X[P].2019-01-11.
    [3]
    Wang C, Zhou MQ, Huang WC. Separation and structural confirmation of 5-methoxybenzo[d]oxazole-2(3H)-thione from key intermediate of omeprazole[J]. Chin J Synth Chem(合成化学), 2018, 26(4):284?287.
    [4]
    CFDA.The technical guidelines for the preparation and structural confirmation of chemical drug apis[EB/OL].(2007-08-23)[2019-10-20].http://www.cde.org.cn/zdyz.do?method=largePage &id=2067.
    [5]
    ICH.Impurities in new drug substances(Q3A)[EB/OL].(2006-10-25)[2019-10-21].https://www.ich.org/page/quality-guidelines.
    [6]
    Compania Uriach Y.Rupatadine salt as an antihistaminic agent:CN,
    201180030958. X[P].2013-03-06[2019-10-20].
    [7]
    Li LL.Study on the synthesis and impurity of rupatadine fumarate (富马酸卢帕他定的合成及杂质研究)[D].Hangzhou:Zhejiang University,2015.
    [8]
    Zhao X.synthesis The,structure confirmation and qualitative analysis of rupatadine fumarate (富马酸卢帕他定的化学合成、结构确证和质量分析)[D].Jinan: Shandong University,2008.
    [9]
    Hu CQ,Zhang X.Current situation and the trend in impurity profiling of chemical drugs[J].Acta Pharm Sin(药学学报),2019,54(12):2214?2231.

Catalog

    Article views (214) PDF downloads (531) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return